Richard Newton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard Newton has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
David Castle
Professor, The University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia
10 shared publications- David Castle
University of Tasmania
7 shared publications George Couch
5 shared publications- James E. Redman
University Chemical Laboratory, University of Cambridge, Lensfield Road, Cambridge, UK
5 shared publications - Lorenz Wernisch
MRC Biostatistics Unit, Robinson Way, Cambridge, CB2 0SR, UK
5 shared publications Peter Bosanac
Associate Professor, The University of Melbourne, Melbourne, VIC, Australia
5 shared publications
Latest Publications
- Open Access
- 21 May 2025
- Published by Elsevier in Psychiatry Research Communications
- Vol. 5 (2)
A scoping review of treatment for factitious disorder (imposed on self)
- 21 May 2025
- Published by Elsevier in Psychiatry Research Communications
- Vol. 5 (2)
Open AccessA scoping review of treatment for factitious disorder (imposed on self)
- Open Access
- 3 March 2025
- Published by Wiley in International Journal of Eating Disorders
- Vol. 58 (5) , 917-925
Toward Integrated Treatment for Co‐Occurring Borderline Personality Disorder and Eating Disorders: A Clinician Perspective
Objective: It is common practice in Australia for co‐occurring borderline personality disorder (BPD) and eating disorders (ED) to be treated separately. The objective of this research was to review features these disorders share, evidence‐based approaches used for treating these disorders in isolation, clinicians' experiences of delivering treatment for co‐occurring BPD and ED, and finally to explore integrated approaches to treating this dual diagnosis.Method: A qualitative approach was used to examine interview transcripts of 10 clinicians employed at specialist outpatient services for severe BPD or severe ED. Interview transcripts were analyzed using thematic analysis.Results: Nominated features shared by BPD and ED were emotion dysregulation, impulsivity, and interpersonal difficulties. Clinicians endorsed a range of therapeutic approaches for this dual diagnosis patient group, as well as an eclectic approach utilizing a combination of treatment features. Most clinicians proposed an ideal program duration of 6–12 months, with group and individually focused therapy complementing one another to address underlying behavioural drivers and confer lasting clinical benefits.Discussion: This study distills the importance of adopting integrated treatments for people with this dual diagnosis to optimize treatment outcomes. Future research could include soliciting client perspectives on using an integrated treatment approach for this dual diagnosis and trials of this approach to assess acceptability, feasibility, and longer‐term outcomes.Public Significance Statement: This study highlights the merit of concurrently addressing the complex interplay between EDs and BPD via an integrated treatment approach. Streamlining the therapeutic approach can address underlying features of these disorders, improve clinical formulation, and optimize patient outcomes.
- 3 March 2025
- Published by Wiley in International Journal of Eating Disorders
- Vol. 58 (5) , 917-925
Open AccessToward Integrated Treatment for Co‐Occurring Borderline Personality Disorder and Eating Disorders: A Clinician Perspective
Objective: It is common practice in Australia for co‐occurring borderline personality disorder (BPD) and eating disorders (ED) to be treated separately. The objective of this research was to review features these disorders share, evidence‐based approaches used for treating these disorders in isolation, clinicians' experiences of delivering treatment for co‐occurring BPD and ED, and finally to explore integrated approaches to treating this dual diagnosis.Method: A qualitative approach was used to examine interview transcripts of 10 clinicians employed at specialist outpatient services for severe BPD or severe ED. Interview transcripts were analyzed using thematic analysis.Results: Nominated features shared by BPD and ED were emotion dysregulation, impulsivity, and interpersonal difficulties. Clinicians endorsed a range of therapeutic approaches for this dual diagnosis patient group, as well as an eclectic approach utilizing a combination of treatment features. Most clinicians proposed an ideal program duration of 6–12 months, with group and individually focused therapy complementing one another to address underlying behavioural drivers and confer lasting clinical benefits.Discussion: This study distills the importance of adopting integrated treatments for people with this dual diagnosis to optimize treatment outcomes. Future research could include soliciting client perspectives on using an integrated treatment approach for this dual diagnosis and trials of this approach to assess acceptability, feasibility, and longer‐term outcomes.Public Significance Statement: This study highlights the merit of concurrently addressing the complex interplay between EDs and BPD via an integrated treatment approach. Streamlining the therapeutic approach can address underlying features of these disorders, improve clinical formulation, and optimize patient outcomes.
- Open Access
- 5 January 2025
- Published by Taylor & Francis in Psychiatry, Psychology and Law
- Vol. 33 (3) , 517-531
Finding the balance between respecting autonomy and life-saving anorexia nervosa care: an Australian perspective
Use of involuntary treatment or coercion in the treatment and management of eating disorders is controversial, whether from a clinical, legal or ethical standpoint. With particular reference to Victorian reforms to mental health and guardianship legislation, and selected developments elsewhere, this paper reviews the role of law in authorising the use, duration and oversight of use of coercion in the treatment of eating disorders. The paper finds that Victoria’s legislative framework offers appropriate, if incomplete, high-level guidance on minimisation of coercion and avoidance of psychological harm and impairment of therapeutic relationships. The paper concludes that detailed clinical practice guidelines are required to be developed by bodies such as the Chief Psychiatrist in order to adequately accommodate the nuances and complexities of care and treatment of eating disorders.
- 5 January 2025
- Published by Taylor & Francis in Psychiatry, Psychology and Law
- Vol. 33 (3) , 517-531
Open AccessFinding the balance between respecting autonomy and life-saving anorexia nervosa care: an Australian perspective
Use of involuntary treatment or coercion in the treatment and management of eating disorders is controversial, whether from a clinical, legal or ethical standpoint. With particular reference to Victorian reforms to mental health and guardianship legislation, and selected developments elsewhere, this paper reviews the role of law in authorising the use, duration and oversight of use of coercion in the treatment of eating disorders. The paper finds that Victoria’s legislative framework offers appropriate, if incomplete, high-level guidance on minimisation of coercion and avoidance of psychological harm and impairment of therapeutic relationships. The paper concludes that detailed clinical practice guidelines are required to be developed by bodies such as the Chief Psychiatrist in order to adequately accommodate the nuances and complexities of care and treatment of eating disorders.
- Open Access
- 14 November 2023
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 31 (6) , 841-845
What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Objective: To review the usefulness of esketamine for treatment-resistant depression. Method: Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results: Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine, esketamine is given intranasally (under clinical observation), usually in addition to an oral antidepressant. Trials compared esketamine plus antidepressant versus placebo plus antidepressant. At 4 weeks, remission was 37% higher with esketamine/antidepressant than placebo/antidepressant. Speed of response and improvement in suicidality were comparable. In stable remitters on esketamine/antidepressant, 45% relapsed when esketamine was withdrawn over the following 6 months (whereas 25% relapsed on esketamine/antidepressant). Response appears less likely in patients with multiple antidepressant failures. Adverse effects include dissociation, dizziness, nausea, sedation, and headache but no psychosis. Hypertension affected 13%, especially older patients. Dose frequency is twice-weekly for 4 weeks, then weekly/fortnightly thereafter. No abuse has been reported. Unsubsidised cost may be beyond the reach of many Australians. Conclusion: Intranasal esketamine plus antidepressant has been approved by regulators as moderately effective and acceptably tolerable for treatment-resistant depression. Cost is a drawback. Use often needs to be long-term and vigilance for abuse is essential.
- 14 November 2023
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 31 (6) , 841-845
Open AccessWhat clinicians need to know about intranasal esketamine for treatment-resistant depression?
Objective: To review the usefulness of esketamine for treatment-resistant depression. Method: Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results: Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine, esketamine is given intranasally (under clinical observation), usually in addition to an oral antidepressant. Trials compared esketamine plus antidepressant versus placebo plus antidepressant. At 4 weeks, remission was 37% higher with esketamine/antidepressant than placebo/antidepressant. Speed of response and improvement in suicidality were comparable. In stable remitters on esketamine/antidepressant, 45% relapsed when esketamine was withdrawn over the following 6 months (whereas 25% relapsed on esketamine/antidepressant). Response appears less likely in patients with multiple antidepressant failures. Adverse effects include dissociation, dizziness, nausea, sedation, and headache but no psychosis. Hypertension affected 13%, especially older patients. Dose frequency is twice-weekly for 4 weeks, then weekly/fortnightly thereafter. No abuse has been reported. Unsubsidised cost may be beyond the reach of many Australians. Conclusion: Intranasal esketamine plus antidepressant has been approved by regulators as moderately effective and acceptably tolerable for treatment-resistant depression. Cost is a drawback. Use often needs to be long-term and vigilance for abuse is essential.
- 18 January 2023
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 31 (3) , 343-345
Over a decade of an eating disorders treatment program: Where to from here?
Objective: Currently available treatments for eating disorders lack efficacy resulting in poor outcomes for patients. In this paper, we describe a number of issues that we have identified in our clinical service, which are not unique to our treatment program. Conclusions: The issues described are common among eating disorder services worldwide and need to be addressed in order to move the field forward. We provide a number of solutions and research areas that need greater focus so that we are able to improve the efficacy of eating disorder treatment services.
- 18 January 2023
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 31 (3) , 343-345
Over a decade of an eating disorders treatment program: Where to from here?
Objective: Currently available treatments for eating disorders lack efficacy resulting in poor outcomes for patients. In this paper, we describe a number of issues that we have identified in our clinical service, which are not unique to our treatment program. Conclusions: The issues described are common among eating disorder services worldwide and need to be addressed in order to move the field forward. We provide a number of solutions and research areas that need greater focus so that we are able to improve the efficacy of eating disorder treatment services.